7th Dec 2009 12:00
Notification of major interests in shares
December 7, 2009 - Shire plc , the global specialty biopharmaceutical company
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:
Shire plc
2. Reason for the notification State Yes/No An acquisition or disposal of voting rights Yes
An acquisition or disposal of qualifying financial instruments No which may result in the acquisition of shares already issued to
which voting rights are attached
An acquisition or disposal of instruments with similar economic No effect to qualifying financial instruments
An event changing the breakdown of voting rights No Other (please specify): No
3. Full name of person(s) subject to the notification BlackRock Inc obligation:
4. Full name of shareholder(s) (if different from 3.): N/A 5. Date of the transaction (and date on which the 1 December 2009 threshold is crossed or reached if different): 6. Date on which issuer notified: 7 December 2009 7. Threshold(s) that is/are crossed or reached: Above 5% 8. Notified details:
A: Voting rights attached to shares
Class/type of Situation previous Resulting situation after the triggering
shares to transaction if possible the Triggering using the transaction
ISIN CODE Number Number Number Number of voting % of voting of of of rights rights Shares Voting shares Rights Direct Indirect Direct Indirect JE00B2QKY057 N/A N/A N/A N/A 33,336,203 N/A 5.94%
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that may be rights instrument Period/ Date acquired if the instrument is exercised/ converted
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments Resulting situation after the triggering transaction Type of Exercise Expiration Exercise/ Number of % of voting financial price date Conversion voting rights instrument period rights instrument refers to Nominal Delta Total (A+B+C) Number of voting rights % of voting rights 33,336,203 5.94
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
BlackRock Investment Management (UK) Limited - 33,336,203 (5.94%)
On 1 December 2009, the Barclays Global Investors (BGI) business was acquired by BlackRock, Inc. The combined holdings of BlackRock, Inc. following this acquisition triggered this disclosure requirement
Proxy Voting: N/A 10. Name of the proxy holder: 11. Number of voting rights proxy holder will cease to N/A hold: 12. Date on which proxy holder will cease to hold voting N/A
rights: 13. Additional information: BlackRock Compliance Disclosures Team 14. Contact name: Stuart Watchorn
15. Contact telephone number: 020 7743 5741: [email protected]
Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, 01256 894746
For further information please contact:
Investor Relations Clea Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 617 551 9715 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release
www.shire.com
vendorRelated Shares:
Shire